Global healthcare company - Viatris has, on November 29, completed the sale of its global biosimilars business to Biocon Biologics Limited, subsidiary of Biocon Limited for USD 3.335 billion for stock and cash consideration. The sale of global biosimilars business marks monumental moment to develop a future direction for Viatris that will not only unlock immediate value but will also …
